acut
bronchiol
respons
high
morbid
infant
club
cell
protein
kda
major
pneumoprotein
secret
club
cell
bronchial
epithelium
elimin
renal
pathway
seem
biomark
epitheli
damag
asthma
howev
valu
marker
acut
bronchiol
sever
later
recurr
wheez
uncertain
especi
valu
urinari
assay
purpos
prospect
observ
analyt
studi
conduct
clermontferrand
univers
hospit
correl
serum
level
clinic
sever
bronchiol
hospit
infant
age
less
year
analyz
correl
serum
urinari
level
wainwright
score
immedi
morbid
due
bronchiol
causal
virus
recurr
wheez
year
inclus
infant
serum
correl
acut
bronchiol
sever
p
urinari
p
multivari
analysi
urinari
correl
mainli
urinari
retinol
bind
protein
rbp
r
p
ratio
correl
significantli
sever
p
level
correl
recurr
wheez
year
urinari
could
use
biomark
acut
bronchiol
specif
indic
noninvas
assay
would
particularli
use
young
infant
popul
sever
factor
must
taken
account
interpret
mainli
tubular
function
studi
need
assess
factor
acut
bronchiol
club
clara
cell
protein
infant
morbid
sever
introduct
acut
viral
bronchiol
mainli
caus
respiratori
synciti
viru
rsv
human
rhinoviru
one
common
respiratori
diseas
earli
childhood
major
health
problem
worldwid
sever
bronchiol
character
extens
inflamm
edema
airway
increas
mucu
product
necrosi
airway
epitheli
cell
admiss
hospit
bronchiol
young
age
associ
increas
risk
recurr
wheez
import
know
whether
initi
epitheli
injuri
respons
sever
sequela
whether
inflammatori
respons
viral
agent
predispos
patient
relaps
much
effort
made
identifi
novel
biolog
marker
measur
cours
acut
bronchiol
clinic
effect
predict
diseas
sever
later
wheez
team
studi
epitheli
injuri
biomark
acut
bronchiol
found
correl
serum
level
serumsolubl
receptor
advanc
glycat
endproduct
sever
acut
bronchiol
risk
wheez
bronchiti
club
cell
protein
major
pneumoprotein
secret
club
cell
formerli
clara
cell
termin
bronchiolar
epithelium
diffus
airway
serum
along
concentr
gradient
elimin
urin
renal
clearanc
possess
antiinflammatori
antioxid
immunosuppress
antitumor
proprieti
vitro
antiinflammatori
activ
inhibit
phospholipas
activ
arachidon
acid
product
prostaglandin
leukotrien
releas
therebi
counter
sever
chronic
pulmonari
diseas
serum
assay
often
use
assess
lung
injuri
rare
urinari
assay
link
level
asthma
alreadi
studi
relat
acut
bronchiol
receiv
less
attent
set
determin
whether
could
sever
biomark
epitheli
damag
acut
bronchiol
recurr
wheez
sequela
also
sought
evalu
util
noninvas
urinari
assay
view
young
target
popul
concern
studi
receiv
ethic
committe
approv
de
protect
de
personn
sud
est
vi
franc
approv
number
patient
control
includ
parent
gave
fulli
inform
written
consent
main
object
studi
evalu
correl
serum
level
acut
bronchiol
clinic
sever
hospit
children
age
year
secondari
object
studi
correl
serum
urinari
concentr
urinari
clinic
sever
serum
urinari
level
relev
viru
rsv
rhinoviru
rhinoviru
type
obtain
genotyp
case
rhinoviru
immedi
morbid
mortal
recurr
wheez
year
inclus
acut
bronchiol
sever
rate
mild
moder
sever
wainwright
clinic
graviti
score
base
respiratori
rate
respiratori
effort
inclus
pediatr
emerg
medic
histori
collect
admiss
perinat
person
histori
gestat
age
birth
weight
deliveri
rout
exist
atop
site
presenc
immedi
complic
bronchial
superinfect
pneumothorax
atelectasi
whether
oral
inhal
corticosteroid
use
paraclin
assess
baselin
includ
ml
blood
sampl
serum
assay
ml
urin
sampl
urinari
urinari
retinol
bind
protein
rbp
adjust
renal
function
determin
nasopharyng
sampl
virolog
analysi
chest
xray
respiratori
complic
recurr
wheez
assess
immedi
morbid
mortal
assess
hospit
data
length
hospit
stay
use
durat
enter
nutrit
parenter
rehydr
oxygen
therapi
mural
highdos
respiratori
support
continu
airway
pressur
bilevel
posit
airway
pressur
invas
mechan
ventil
superinfect
document
biolog
radiolog
ventil
disord
ga
effus
document
radiolog
bronchospasm
use
mimet
inhal
corticosteroid
death
famili
contact
phone
thirti
day
year
inclus
elicit
inform
respiratori
event
bronchiol
recurr
wheez
wheez
without
consult
respiratori
treatment
oral
corticosteroid
respiratori
physiotherapi
hospit
respiratori
reason
recurr
wheez
diagnosi
retain
third
episod
bronchiol
use
longterm
treatment
recurr
wheez
diagnosi
anoth
pediatrician
infant
age
year
enrol
serum
control
group
anesthesia
consult
plan
surgeri
health
statu
evalu
complet
medic
checkup
clinic
questionnair
children
histori
pulmonari
diseas
wheez
cardiopulmonari
diseas
chronic
pulmonari
diseas
prematur
ongo
infecti
process
exclud
infant
age
year
enrol
urin
control
group
standard
consult
pediatr
emerg
medic
checkup
questionnair
infant
histori
acut
bronchiol
prematur
week
ongo
pulmonari
infect
treat
eczema
firstdegre
asthma
exclud
statist
analys
perform
stata
adjust
factor
clinic
relev
statist
signific
p
univari
analysi
stepwis
select
appli
enter
p
remov
p
result
shown
regress
coeffici
confid
interv
ci
test
twosid
p
consid
statist
signific
studi
includ
infant
mean
age
month
day
month
among
famili
histori
asthma
case
present
inaugur
acut
bronchiol
classifi
mild
case
moder
sever
wainwright
score
age
invers
correl
mean
durat
hospit
stay
longer
youngest
infant
r
p
control
serum
interview
n
control
urinari
differ
age
month
vs
month
p
sex
serum
control
girl
vs
p
observ
case
control
respect
immedi
complic
detail
support
inform
one
year
inclus
accord
parent
interview
infant
develop
recurr
wheez
virolog
analysi
perform
case
infant
infect
isol
rsv
isol
rhinoviru
coinfect
rsvrhinoviru
rsv
infect
correl
sever
clinic
present
accord
wainwright
score
p
figur
statist
analysi
show
impact
level
sex
birth
term
weight
birth
cesarean
section
differ
observ
mean
serum
urinari
sever
studi
conduct
relationship
asthma
relat
acut
bronchiol
receiv
less
attent
avail
pediatr
studi
johansson
et
al
show
increas
serum
level
case
compar
healthi
infant
author
highlight
significantli
increas
infect
rsv
compar
influenza
viru
iv
parainfluenza
viru
piv
virus
result
serum
level
seem
varianc
result
despit
outbreak
rsv
level
compar
case
control
moreov
correl
observ
level
sever
score
clinic
graviti
morbid
signific
differ
type
viru
found
note
similar
serum
level
includ
sever
affect
infant
howev
result
urinari
level
seem
concord
johansson
et
al
increas
level
case
compar
healthi
infant
also
correl
sever
score
durat
stay
type
stay
higher
valu
sever
case
increas
level
acut
bronchiol
could
result
viral
damag
epitheli
barrier
well
describ
fulmin
form
disrupt
epitheli
barrier
deep
lung
could
lead
enhanc
leakag
serum
secondarili
urin
studi
serum
urinari
level
correl
suggest
discord
result
could
explain
part
limit
number
blood
sampl
compar
urin
sampl
vs
respect
furthermor
case
mainli
affect
mild
moder
form
result
interest
sever
influenc
factor
must
taken
consider
interpret
main
variat
factor
like
tubular
function
take
account
integr
assay
rbp
marker
tubular
reabsorpt
function
multivari
analysi
show
strong
correl
rbp
urinari
level
argu
systemat
adjust
rbpu
anoth
renal
function
marker
urinari
creatinin
correl
acut
bronchiol
sever
evalu
wainwright
score
likewis
hydrat
statu
time
sampl
also
taken
account
sever
case
youngest
infant
vulner
feed
difficulti
mark
respiratori
effort
subsequ
dehydr
factor
variat
need
integr
multivari
model
precis
interpret
level
environment
factor
physiolog
data
age
sex
time
sampl
physic
activ
fulli
describ
final
avail
pediatr
studi
show
lower
level
asthmat
patient
result
indic
measur
viral
episod
predict
recurr
wheez
year
followup
period
chose
admittedli
short
analyz
risk
asthma
long
term
also
still
unclear
whether
low
level
induc
asthma
long
term
whether
chronic
inflamm
respons
declin
club
cell
product
conclus
higher
urinari
level
observ
acut
bronchiol
correl
sever
noninvas
biomark
epitheli
damag
particularli
use
infant
popul
sever
factor
taken
account
interpret
mainli
tubular
function
reason
use
assay
categoryspecif
acut
bronchiol
could
thu
consid
exampl
sever
case
rsv
infect
famili
histori
asthma
